LINC01123 promotes immune escape by sponging miR-214-3p to regulate B7–H3 in head and neck squamous-cell carcinoma

Abstract

Numerous studies have shown that long noncoding RNAs (LncRNAs) are involved in the development and immune escape of head and neck squamous-cell carcinoma (HNSCC). However, the specific regulatory mechanisms by which LINC01123 regulates HNSCC and its correlation with immunity remain unclear. Therefore, this study’s primary purpose was to explore the mechanisms by which LINC01123 regulates the immune escape and progression of HNSCC. This study confirmed that LINC01123 is competitively bound to miR-214-3p, and miR-214-3p specifically targets B7–H3. The effects of LINC01123, B7–H3, and miR-214-3p on tumor progression, CD8+T-cell-mediated immune response, and the tumorigenicity of HNSCC in vitro and in vivo were examined through the downregulation or upregulation of LINC01123, B7–H3, and miR-214-3p. Our results indicated that LINC01123 and B7–H3 were highly expressed in HNSCC and are associated with poor prognosis in patients. Notably, overexpression of LINC01123 or B7–H3 or downregulation of miR-214-3p inhibited the function of CD8+T cells and promoted the progression of HNSCC. Therefore, LINC01123 acts as a miR-214-3p sponge to inhibit the activation of CD8+T cells and promote the progression of HNSCC by upregulating B7–H3.

Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma

“…Second, we focused on the roles of circWDR62 in TMZ resistance and malignant progression. More detailed studies are necessary to explore the role of circWDR62 in other biological behaviours of glioma, including immune escape and tumour energy metabolism [ 53 ]. In addition, the upstream regulatory mechanism of circWDR62 in TMZ-resistant glioma cells and tissues also worthy of further exploration.…”

Characterization of tumor immune microenvironment and cancer therapy for head and neck squamous cell carcinoma through identification of a genomic instability-related lncRNA prognostic signature

“…However, there are rare consistent prognostic biomarkers for HNSCC due to high heterogeneous genomics and complex etiology ( Beck and Golemis, 2016 ; Yang et al, 2020 ). Studies have revealed that lncRNAs hold potential in the pathogenesis, diagnosis, prognosis, and targeted treatment of patients with HNSCC by promoting DNA damage and regulating the cell cycle ( Guglas et al, 2017 ; Wang Y. et al, 2020 ; Jiang et al, 2022 ; Li et al, 2022 ), while the role of GI-associated with lncRNAs in the prediction of TIME and therapeutics for HNSCC has not been systematically assessed.…”

“…Ritu Chaudhary et al found that LINC00460 was abundant in HNSCC tissue and associated with poor patient survival ( Chaudhary et al, 2020 ). Several lncRNA-based signatures showed prognostic effect ( Liu G. et al, 2018 ; Wang et al, 2021 ) and correlated with TIME landscape ( Cao et al, 2022 ; Li et al, 2022 ). However, rare studies have reported GI-related lncRNAs potentials in predicting TIME and therapies in HNSCC.…”

Tumor immunotherapy: Mechanisms and clinical applications

“…35 Studies have reported that B7-H3 is highly expressed in HNSCC, blocking the expression of B7-H3 reduces the recruitment of MDSCs and M2-TAMs in the tumor microenvironment and promotes the activation of T cells, and enhances the antitumor immune response. 36,37 The receptor of scavenger receptor type B-1(SCARB1) expressed on MDSCs cells is highly affinitive for high-density lipoprotein (HDL), and synthetic high-density lipoprotein nanoparticles (HDL-NP) specifically bind to this receptor. In a mouse melanoma model, HDL-NP binding to SCARB1 attenuated immunosuppression and activated T cell-mediated immune responses, which reduced tumor growth and improved survival in mice.…”

“…The expression of B7‐H3 protein is low in normal human tissues such as the prostate, breast, placenta, liver, colon, and lymphoid organs 35 . Studies have reported that B7‐H3 is highly expressed in HNSCC, blocking the expression of B7‐H3 reduces the recruitment of MDSCs and M2‐TAMs in the tumor microenvironment and promotes the activation of T cells, and enhances the antitumor immune response 36,37 . The receptor of scavenger receptor type B‐1(SCARB1) expressed on MDSCs cells is highly affinitive for high‐density lipoprotein (HDL), and synthetic high‐density lipoprotein nanoparticles (HDL‐NP) specifically bind to this receptor.…”